menu
    • menu
    [{"orgOrder":0,"company":"Scandinavian Biopharma","sponsor":"G\u00f6teborg University | Aurevia | Sahlgrenska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Etvax Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Scandinavian Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scandinavian Biopharma \/ G\u00f6teborg University | Aurevia | Sahlgrenska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Scandinavian Biopharma \/ G\u00f6teborg University | Aurevia | Sahlgrenska University Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Scandinavian Biopharma

    Menu

    Scandinavian Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Scandinavian Biopharma

                            Sweden arrow
                            Pharma MES 2025
                            Not Confirmed

                            Scandinavian Biopharma

                            Sweden arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etvax Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Göteborg University | Aurevia | Sahlgrenska University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Bridging Study to Assess the New Formulation of ETVAX

                            Details : Etvax Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vaccine-Preventable Diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 05, 2022

                            Lead Product(s) : Etvax Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Göteborg University | Aurevia | Sahlgrenska University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth